#JACCCardioOnc study provides the first comprehensive timeline of cardiac anatomical, functional, and molecular changes occurring during the progression of anthracycline-induced #cardiotoxicity in mice. bit.ly/3whP5uM #CardioOnc

Fascinating Nature Reviews Cardiology review by Dr. Bonnie Ky and team about the links between cardiovascular disease and cancer🫀🧬 nature.com/articles/s4156…

Nueva edición del MASTER ONLINE DE CARDI-ONCO-HEMATOLOGIA (cuarta edición ) hasta 25 septiembre. Con la excelencia única en formación de la Sociedad Española de imagen Cardiaca. información completa: cutt.ly/sezXy6L6 Formulario : cutt.ly/oezZx1mV

La cinquena sessió d'actualització en cardiologia del curs serà al febrer, concretament el dia 3/2 i tractarà sobre Cardio-Oncologia per les guàrdies, maneig del pacient agut. Parlarem sobre: 🔴Dolor toràcic 🔴Embassament pericàrdic 🔴Etc. Coneix les altres sessions⬇️

Diving into the intricacies of ICI & VEGFI combination trials 🧪: Disparity in CV exclusion criteria, baseline traits & #MACE reporting present challenges for understanding incidence & severity of events w/ these combinations. Learn more: bit.ly/3UJ7muz #JACCCardioOnc

Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. #EHJ academic.oup.com/eurheartj/adva… #anthracycline #CVD #toxicity #HF European Society of Cardiology Journals European Society of Cardiology

The risk for ATE varies according to sex, age, and cancer progression and type. Antithrombotic therapy after ATE is associated with improved survival among patients with cancer. bit.ly/3xmxmSV #JACCCardioOnc #CardioOnc #VTE

If you were not able to watch it live, below is the link to the BHF Live & Ticking July 2024 – Cancer and the heart youtu.be/kFbWg-RkOE4?si… via YouTube

Immunological therapies revolutionized #cancer treatment over the last decade. #CVtoxicities associated with these therapies emerged as an important consideration. I am honoured to contribute to this ESC/HFA position paper Heart Foundation Cancer Institute NSW …ry-wiley-com.ezproxy.newcastle.edu.au/doi/10.1002/ej…

Nuevas guías de #fibrilacionauricular de European Society of Cardiology #ESCCongress.  Las guías son menos extensas que las previas 📂Documento disponible en academic.oup.com/eurheartj/adva… Vamos con mini-hilo 🧵con algunas de las principales novedades! ⤵️⤵️

📌 Habemos Guías Nuevas 🇪🇺 de Angina Estable 🫀 (los clásicos nunca mueren) 📝Primeras impresiones y novedades-cambios en este hilo 🧵👇👇 En resumen, me parecen unas muy buenas GPC. Directas, claras, simplificando mensajes 🖖 #ESCCongress2024

SAVE THE DATE!! If interested in #CardioOnc, don’t miss the European Society of Cardiology Cardio-Oncology summit 2025 📅 20-21 June 2025 📍 Florence, Italy 🇮🇹 #ESCCongress #ESCCongress2024

Finerenona ▶️ Nuevo pilar para el tratamiento de los pacientes con IC y FEVI preservada ❗️ FINEARTS-HF @nejm #ESCCongress Finerenona vs placebo en 👥 con IC-FEp ✅ Reducción del 16% en el objetivo primario del estudio (muerte CV o eventos descompensación IC) (rate ratio,

🔥#ESC2024 SUCCOUR-MRI shows benefit of GLS-guided cardioprotection in patients treated w anthracyclines🔥 🔥Congratulations and 🙏Tom Marwick dineshpmcc & team! Time to add GLS European Society of Cardiology #CardioOnc risk stratification? European Society of Cardiology Journals Teresa López Fdez

SUCCOUR-MRI randomized pts w GLS decline to cardioprotection vs no treatment and showed benefit. Honored to write the Editorial with my #Oncology colleagues Inova Schar Cancer Institute on how this informs our joint care Inova European Society of Cardiology Journals academic.oup.com/eurheartj/arti…

Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in #PARAGON-HF trial 👥 4795 ➡️23.2% had anaemia at randomization and 5.6% were treated with iron at baseline. ⏰median follow-up of 2.9 years 👥with anaemia were at significantly ⬆️ risk for total HF🏥

📲Teresa López Fernández realiza una valoración sobre los estudios presentados sobre cardio-oncología en el ESC Congress 2024. Sigue el [POST] de #laSECtelleva y consigue la acreditación CASEC hoy, antes de las 23.59 h👉 lasectelleva.secardiologia.es

✅After #ESCCongress we are facing a #HFpEF revolution‼️ ➡️From now a triple or quadruple therapy (in case of obesity) will be the cornerstone of therapy ➡️We need a practical comprehensive approach for established & emergent #HFpEF treatments ↪️So this is Nicolas Manito proposal:

Today was published the EMPACARD - PILOT Trial!!! The first prospective study using SGLT2i like prevention strategy of CTRCD!!! Thanks Vanesa Gregorietti Teresa López Fdez Diego Costa Lourdes M. Figueiras-Graillet Juan Carlos Plana Juliana Salas Joerg Herrmann iLACO International Cardio-Oncology Society Soc Esp Cardiología ACORA

In this #JACCCardioOnc review, Dr. David Gent, et al cover the breadth of what is known about #CVD in the adult #HCT population, focusing on acute & late complications, risk prediction, surveillance, & treatment of complications. bit.ly/3ZeW97w #CardioOnc